StreetInsider.com News Articles

Editas Medicine grants stock options to new chief medical officer

Wed, 09 Sep 2026 09:00:12 -0400

Editas Medicine, Inc. (Nasdaq: EDIT) announced an inducement stock option grant to its newly appointed Chief Medical Officer, Daniel Ory, M.D., according to a company statement.

The Editas Medicine Board of Directors approved a stock option allowing Dr. Ory to purchase up to 950,000 shares of common stock at $3.03 per share, which was the closing price on the date of the grant. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4).

The options vest over four years, with 25% of shares vesting on the 15th day of the month immediately following the first anniversary of Dr. Ory's start date.

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

Wed, 09 Sep 2026 09:00:00 -0400

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Daniel Ory, M.D. In connection with Dr. Ory’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Ory as an inducement material to Dr. Ory entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 950,000 shares of Editas Medicine

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

Wed, 09 Sep 2026 09:00:00 -0400

Editas Medicine names Dan Ory as chief medical officer

Tue, 08 Sep 2026 07:00:32 -0400

Editas Medicine, Inc. (Nasdaq: EDIT) named Dan Ory, M.D., as chief medical officer, effective Sept. 8, 2026, according to a press release from the Cambridge, Mass.-based gene editing company.

Dr. Ory brings more than 25 years of experience in cardiovascular medicine and genetic medicine development. He will oversee Editas's clinical development strategy and operations, with a focus on advancing EDIT-401, the company's lead in vivo development candidate for hyperlipidemia, toward clinical trials.

Before joining Editas, Dr. Ory served as chief medical officer at Arbor Biotechnologies, where he led clinical development for an in vivo gene editing program. Prior to that role, he

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Tue, 08 Sep 2026 07:00:00 -0400

Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development

Appointment strengthens executive leadership team as Editas advances EDIT-401 toward clinical development

CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced the appointment of Dan Ory, M.D., as Chief Medical Officer, effective today.

With more than 25 years of experience spanning biotechnology leadership, cardiovascular medicine, and the development of genetic medicines, Dr. Ory will

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Tue, 08 Sep 2026 07:00:00 -0400

Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development

Appointment strengthens executive leadership team as Editas advances EDIT-401 toward clinical development

With more than 25 years of experience spanning biotechnology leadership, cardiovascular medicine, and the development of genetic medicines, Dr. Ory will

Editas Medicine to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 09:00:00 -0400

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September:

Wells Fargo Healthcare Conference
Format: Fireside Chat
Date: Tuesday, September 8
Time: 4:30 p.m. ET
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, September 10
Time: 3:55 p.m. ET
Location: New York, NY

To access the live webcast of Editas Medicine’s Fireside

Editas Medicine to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 09:00:00 -0400

Wells Fargo Healthcare Conference
Format: Fireside Chat
Date: Tuesday, September 8
Time: 4:30 p.m. ET
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, September 10
Time: 3:55 p.m. ET
Location: New York, NY

To access the live webcast of Editas Medicine’s Fireside

Ladenburg Thalmann Starts Editas Medicine (EDIT) at Buy

Tue, 18 Aug 2026 06:35:02 -0400

Ladenburg Thalmann initiates coverage on Editas Medicine (NASDAQ: EDIT) with a Buy rating and a price target of $6.00.

For an analyst ratings summary and ratings history on Editas Medicine click here. For more ratings news on Editas Medicine click here.

Shares of Editas Medicine closed at $2.84 yesterday.

Form SCHEDULE 13G Editas Medicine, Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26933321.html

Form SCHEDULE 13G Editas Medicine, Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26933321.html

Form 3 Editas Medicine, Inc. For: Aug 06 Filed by: Ellinor Patrick Thomas II

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892200.html

Form 3 Editas Medicine, Inc. For: Aug 06 Filed by: Ellinor Patrick Thomas II

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892200.html

Form 4 Editas Medicine, Inc. For: Aug 06 Filed by: Ellinor Patrick Thomas II

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892206.html

Form 4 Editas Medicine, Inc. For: Aug 06 Filed by: Ellinor Patrick Thomas II

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892206.html

Editas Medicine (EDIT) Tops Q2 EPS by 12c

Wed, 05 Aug 2026 16:45:37 -0400

Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.15), $0.12 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $11.89 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

Form 4 Editas Medicine, Inc. For: Aug 03 Filed by: Parison Amy

Wed, 05 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260805/26874176.html

Form 4 Editas Medicine, Inc. For: Aug 03 Filed by: Parison Amy

Wed, 05 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260805/26874176.html

Form 10-Q Editas Medicine, Inc. For: Jun 30

Wed, 05 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26873964.html

Form 10-Q Editas Medicine, Inc. For: Jun 30

Wed, 05 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26873964.html

Form 8-K Editas Medicine, Inc. For: Aug 03

Wed, 05 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260805/26873704.html

Form 8-K Editas Medicine, Inc. For: Aug 03

Wed, 05 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260805/26873704.html

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Wed, 05 Aug 2026 16:01:00 -0400

EDIT-401 on track for CTN submission this month with data update in Q1 2027

Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a) and ApoB with EDIT-401 in non-human primates

Recent financing strengthens Company’s capital position, supporting continued advancement of EDIT-401 program, with cash runway into the second half of 2028

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Wed, 05 Aug 2026 16:01:00 -0400

EDIT-401 on track for CTN submission this month with data update in Q1 2027

Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a) and ApoB with EDIT-401 in non-human primates

Recent financing strengthens Company’s capital position, supporting continued advancement of EDIT-401 program, with cash runway into the second half of 2028

Editas Medicine adds cardiovascular geneticist to its board

Tue, 04 Aug 2026 16:15:46 -0400

Editas Medicine (Nasdaq: EDIT) appointed Patrick T. Ellinor, M.D., Ph.D., to its board of directors, effective August 6, 2026, according to a press release from the Cambridge, Mass.-based gene editing company.

Dr. Ellinor serves as Executive Director of the Heart and Vascular Institute at Mass General Brigham and as Director of the Cardiovascular Disease Initiative at the Broad Institute of MIT and Harvard. He also holds a professorship at Harvard Medical School.

His research has focused on the genetics of cardiovascular disease, including genetic analyses of atrial fibrillation, with work spanning human genetics, genomics, computational biology, and artificial intelligence.

Editas board chair Jessica